Statin-induced inhibition of the rho-signaling pathway activates PPARα and induces HDL apoA-I

Journal of Clinical Investigation

Volumn 107, Issue 11, 2001, Pages 1423-1432

  Martin, Geneviève ^a   Duez, Hélène ^a   Blanquart, Christophe ^a   Berezowski, Vincent ^a   Poulain, Philippe ^a   Fruchart, Jean Charles ^a   Najib Fruchart, Jamila ^a   Glineur, Corine ^a   Staels, Bart ^a,b  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CERIVASTATIN; DACTINOMYCIN; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GERANYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PITAVASTATIN; PYROPHOSPHATE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0034994075     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10852     Document Type: Article

References (69)

1. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting
2. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
3. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
4. Beyond LDL cholesterol reduction
5. Effect of statins on metabolism of apoB-containing lipoproteins in hypertriglyceridemic men
6. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease
7. Atheroprotective mechanisms of HDL
8. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
9. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study
10. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease
11. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses
12. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
13. Pleiotropic effects of statins in atherosclerosis and diabetes
14. Low-density lipoprotein-independent effects of statins
15. Direct vascular effects of HMG-CoA reductase inhibitors
16. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
17. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC
18. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
19. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
20. Current perspectives on statins
21. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
22. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
23. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
24. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha anal gamma
25. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
26. Mechanism of action of fibrates on lipid and lipoprotein metabolism
27. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
28. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin- 1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
29. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat
30. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
31. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element
32. A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity
33. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation
34. RhoG GTPase controls a pathway that independently activates Rac1 and Cdc42Hs
35. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
36. Lovastatin increases apolipoprotein A-I levels in subjects with isolated reductions in high density lipoproteins
37. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism
38. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a
39. Sterol regulator element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes
40. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand
41. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis
42. Differential activation of peroxisome proliferator-activated receptors by eicosanoids
43. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
44. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
45. Interleukin-4-dependent production of PPARgamma ligands in macrophages by 12/15-lipoxygenase
46. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner
47. Clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency
48. The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat
49. Biotransformation of cerivastatin in mice, rats, and dogs in vivo
50. Effect of low density lipoproteins, high density lipoproteins, and cholesterol on apolipoprotein A-I mRNA in Hep G2 cells
51. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
52. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay
53. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture
54. Specific labeling of isoprenylated proteins: Application to study inhibitors of the post-translational farnesylation and geranylgeranylation
55. The prenylation of proteins
56. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha
57. Regulation of the mevalonate pathway
58. Protein lipidation in cell signaling
59. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
60. Bacterial toxins that target Rho proteins
61. Rho GTPases and the actin cytoskeleton
62. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway
63. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs
64. The small GTP-binding protein rho activates c-Jun N-terminal kinases/stress-activated protein kinases in human kidney 293T cells. Evidence for a Pak-independent signaling pathway
65. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: Regulation by insulin
66. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth
67. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain
68. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of PPAR alpha transcriptional activity mediated by stat5b
69. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism